CalGo

Calgo is a biotechnology company focused on developing novel small molecule therapeutics that modulate calcium signaling pathways. The company's primary research centers on the calcium-sensing receptor (CaSR) to address disorders related to mineral metabolism and parathyroid function. Calgo's lead programs are currently in the pre-clinical stage, aiming to provide more effective treatments for conditions such as hypocalcemia and secondary hyperparathyroidism. By leveraging its expertise in calcium homeostasis, the company seeks to develop targeted therapies that offer improved safety and efficacy profiles compared to existing standard-of-care treatments.